Rytary (Carbidopa-Levodopa ER) in Parkinson’s Disease

Parkinson’s disease (PD) has long presented challenges in medication delivery. A staple in more advanced disease control, carbidopa-levodopa requires multiple daily dosing with supratherapeutic levels leading to dyskinesias and subtherapeutic concentrations leading to troublesome “off” time. Sinemet (carbidopa-levodopa), Sinemet Controlled-Release (CR), and their respective generic equivalents have been used in PD for decades, but leave […]
Read More